Coumarin Therapy and Platelet Aggregation

Receiving Coumarin Anticoagulant Therapy

Platelet Phagocytosis and Aggregation

The addition of latex particles to native (no anticoagulant) or citrated human platelet-rich plasma (PRP), or to a once-washed platelet suspension causes platelet aggregation. This aggregation is associated with phagocytosis of the latex particles by the platelets and appears to be due to release of adenosine diphosphate (ADP) from the platelets. Adenosine and adenosine monophosphate, which are...

Platelet lipid composition and platelet aggregation

Abnormal plasma lipoproteins in patients with liver disease are associated with an increase in erythrocyte cholesterol concentration and a raised erythrocyte cholesteroVphosphoEpid molar ratio. We hypothesized that their platelets would also have an increased cholesteroVphospholipid ratio and that this might affect aggregation in vitro. Platelet aggregation by adrenaline and ADP was measured in...

Platelet aggregation, platelet serotonin and pancreatitis.

Pharmacogenetics-based coumarin therapy.

To reduce the risk of hemorrhage, experts advocate prescribing the anticipated therapeutic dose to patients who are beginning coumarin therapy, but until now there was no accurate way to estimate that dose. Using pharmacogenetics-based coumarin therapy, clinicians can now estimate the therapeutic dose by genotyping their patients for single nucleotide polymorphisms (SNPs) that affect coumarin m...